Extensive T-Cell Profiling Following SARS-CoV-2 mRNA Vaccination in Multiple Sclerosis Patients Treated with DMTs
Pathogens · 2025
DOI: 10.3390/pathogens14030235 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pathogens, 2025. Verfasst von Hannah Solchenberger und 6 weiteren Autor:innen. Beteiligte Einrichtung: Center of Clinical Neuroscience, Department of Neurology, Carl Gustav Carus University Hospital, Technical University Dresden, 01307 Dresden, Germany. Hauptthemen laut MEDLINE: Multiple Sclerosis, SARS-CoV-2, COVID-19, COVID-19 Vaccines. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Technical University of Dresden, Gemeinnuetzige Hertie Stiftung.
Abstract (Originalsprache)
Disease-modifying therapies (DMTs) are known to impact cellular and humoral immune response in persons with multiple sclerosis (pwMS). In this study, we performed in-depth SARS-CoV-2-specific T-cell profiling using flow cytometry. T-cell immunity in pwMS with or without DMTs was evaluated before a first SARS-CoV-2 messenger ribonucleic acid (mRNA) vaccination and at one-, two- and six-month follow-up. T-cell stimulation without SARS-CoV-2-specific antigens was used as a control. T-cell response was compared to B-cell response by evaluating SARS-CoV-2-specific antibodies. We observed an upregulation of specific subpopulations of SARS-CoV-2 spike-specific CD4+ T cells. Thus, our results demonstrate the induction of a broad and distinct CD4+ T-cell response in pwMS even on anti-CD20 treatment and sphingosine-1-phosphate receptor modulation after SARS-CoV-2 mRNA vaccination. This was particularly seen in CD4+high and CD4+CD154+ T cells. Our results do not support the induction of a CD8+ T-cell immune response. While humoral immune response was impaired in pwMS during ocrelizumab and fingolimod treatment, there was evidence of a compensatory upregulation of subpopulations of SARS-CoV-2-specific CD4+ T cells at low levels of seroconversion in pwMS. In conclusion, our results provide important insights into the mechanisms of the adaptive immune response in pwMS following SARS-CoV-2 mRNA vaccination.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center of Clinical Neuroscience, Department of Neurology, Carl Gustav Carus University Hospital, Technical University Dresden, 01307 Dresden, Germany.
- Medical Faculty Carl Gustav Carus, Technical University Dresden, Experimental Transfusion Medicine, 01307 Dresden, Germany.
- Institute for Transfusion Medicine Dresden, German Red Cross Blood Donation Service North-East, 01307 Dresden, Germany.
ORCID-Profile: Hannah Solchenberger, Marcus Odendahl, Dirk Schriefer, Tjalf Ziemssen, Katja Akgün
Förderung
- Technical University of Dresden
- Gemeinnuetzige Hertie Stiftung
Zitieren
APA
Solchenberger, H., Odendahl, M., Schriefer, D., Proschmann, U., Rahbani, G. K. A., Ziemssen, T., & Akgün, K. (2025). Extensive T-Cell Profiling Following SARS-CoV-2 mRNA Vaccination in Multiple Sclerosis Patients Treated with DMTs. Pathogens. https://doi.org/10.3390/pathogens14030235
Vancouver
Solchenberger H, Odendahl M, Schriefer D, Proschmann U, Rahbani GKA, Ziemssen T, et al. Extensive T-Cell Profiling Following SARS-CoV-2 mRNA Vaccination in Multiple Sclerosis Patients Treated with DMTs. Pathogens. 2025. doi:10.3390/pathogens14030235
BibTeX
@article{Solchenberger2025,
author = {Solchenberger, Hannah and Odendahl, Marcus and Schriefer, Dirk and Proschmann, Undine and Rahbani, Georges Katoul Al and Ziemssen, Tjalf and Akgün, Katja},
title = {Extensive T-Cell Profiling Following SARS-CoV-2 mRNA Vaccination in Multiple Sclerosis Patients Treated with DMTs},
journal = {Pathogens},
year = {2025},
doi = {10.3390/pathogens14030235}
}
EUVIMED